Jay M. Young

1.6k total citations
22 papers, 1.3k citations indexed

About

Jay M. Young is a scholar working on Endocrinology, Diabetes and Metabolism, Urology and Psychiatry and Mental health. According to data from OpenAlex, Jay M. Young has authored 22 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Endocrinology, Diabetes and Metabolism, 11 papers in Urology and 10 papers in Psychiatry and Mental health. Recurrent topics in Jay M. Young's work include Hormonal and reproductive studies (13 papers), Urinary Bladder and Prostate Research (11 papers) and Sexual function and dysfunction studies (10 papers). Jay M. Young is often cited by papers focused on Hormonal and reproductive studies (13 papers), Urinary Bladder and Prostate Research (11 papers) and Sexual function and dysfunction studies (10 papers). Jay M. Young collaborates with scholars based in United States, United Kingdom and Australia. Jay M. Young's co-authors include Kevin T. McVary, Li‐Jung Tseng, Joseph L. Camps, Stephen M. Auerbach, Terry Taylor, Thomas P. Segerson, Irwin Goldstein, Keith Bangerter, Barton Wachs and Gregory D. Sides and has published in prestigious journals such as Diabetes Care, Journal of Applied Physiology and The Journal of Urology.

In The Last Decade

Jay M. Young

22 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jay M. Young United States 16 836 712 697 172 167 22 1.3k
Ki Hak Moon South Korea 17 479 0.6× 284 0.4× 313 0.4× 113 0.7× 139 0.8× 49 748
K. Rokkas Greece 13 738 0.9× 254 0.4× 611 0.9× 53 0.3× 94 0.6× 29 916
Roberto Bruzziches Italy 21 669 0.8× 184 0.3× 921 1.3× 62 0.4× 150 0.9× 33 1.3k
C. Souto Brazil 8 394 0.5× 192 0.3× 248 0.4× 64 0.4× 86 0.5× 14 638
Ahmet Gökçe Türkiye 19 358 0.4× 245 0.3× 162 0.2× 64 0.4× 105 0.6× 66 909
Yuanshan Cui China 21 176 0.2× 445 0.6× 313 0.4× 244 1.4× 35 0.2× 116 1.3k
Karl Erik Andersson United States 9 278 0.3× 188 0.3× 199 0.3× 116 0.7× 62 0.4× 12 517
Emre Can Polat Türkiye 16 192 0.2× 137 0.2× 126 0.2× 85 0.5× 71 0.4× 58 723
Giovanni Corona Italy 17 302 0.4× 992 1.4× 664 1.0× 357 2.1× 19 0.1× 24 1.5k
Tomoya Kataoka Japan 13 244 0.3× 95 0.1× 250 0.4× 31 0.2× 47 0.3× 59 527

Countries citing papers authored by Jay M. Young

Since Specialization
Citations

This map shows the geographic impact of Jay M. Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jay M. Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jay M. Young more than expected).

Fields of papers citing papers by Jay M. Young

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jay M. Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jay M. Young. The network helps show where Jay M. Young may publish in the future.

Co-authorship network of co-authors of Jay M. Young

This figure shows the co-authorship network connecting the top 25 collaborators of Jay M. Young. A scholar is included among the top collaborators of Jay M. Young based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jay M. Young. Jay M. Young is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Messing, Edward M., Jason Gee, Daniel R. Saltzstein, et al.. (2012). A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients. Cancer Prevention Research. 5(4). 621–630. 69 indexed citations
2.
Spitz, Aaron, Jay M. Young, Lois Larsen, et al.. (2011). Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer and Prostatic Diseases. 15(1). 93–99. 39 indexed citations
3.
Dwyer, Peter, Con Kelleher, Jay M. Young, et al.. (2008). Long‐term benefits of darifenacin treatment for patient quality of life: Results from a 2‐year extension study. Neurourology and Urodynamics. 27(6). 540–547. 16 indexed citations
4.
Hendricksen, Kees, Donald M. Gleason, Jay M. Young, et al.. (2008). Safety and Side Effects of Immediate Instillation of Apaziquone Following Transurethral Resection in Patients With Nonmuscle Invasive Bladder Cancer. The Journal of Urology. 180(1). 116–120. 19 indexed citations
5.
6.
McVary, Kevin T., Claus G. Roehrborn, Jed Kaminetsky, et al.. (2007). Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. The Journal of Urology. 177(4). 1401–1407. 286 indexed citations
7.
McVary, Kevin T., Joel M. Kaufman, Jay M. Young, & Li‐Jung Tseng. (2007). Sildenafil citrate improves erectile function: a randomised double-blind trial with open-label extension. International Journal of Clinical Practice. 61(11). 1843–1849. 13 indexed citations
8.
Cella, David, Daniel P. Petrylak, Mayer Fishman, et al.. (2006). Role of Quality of Life in Men with Metastatic Hormone-Refractory Prostate Cancer: How Does Atrasentan Influence Quality of Life?. European Urology. 49(5). 781–789. 21 indexed citations
9.
Roehrborn, Claus G., Kevin T. McVary, Sascha Auerbach, et al.. (2006). PD-02.08. Urology. 68. 7–8. 1 indexed citations
10.
Gittelman, Marc, Joe Ramsdell, Jay M. Young, & Tom McNicholas. (2006). Dutasteride Improves Objective and Subjective Disease Measures in Men With Benign Prostatic Hyperplasia and Modest or Severe Prostate Enlargement. The Journal of Urology. 176(3). 1045–1050. 17 indexed citations
11.
Roehrborn, Claus, Jed Kaminetsky, Sascha Auerbach, et al.. (2006). THE EFFICACY AND SAFETY OF TADALAFIL ADMINISTERED ONCE A DAY FOR LOWER URINARY TRACT SYMPTOMS (LUTS) IN MEN WITH BENIGN PROSTATIC HYPERPLASIA (BPH). European Urology Supplements. 5(2). 196–196. 18 indexed citations
12.
McVary, Kevin T., Jed Kaminetsky, Stephen M. Auerbach, et al.. (2006). 1636: The Efficacy and Safety of Tadalafil Administered Once a Day for Lower Urinary Tract Symptoms (LUTS) in Men with Benign Prostatic Hyperplasia (BPH). The Journal of Urology. 175(4S). 527–527. 9 indexed citations
13.
Valiquette, Luc, et al.. (2005). Sustained Efficacy and Safety of Vardenafil for Treatment of Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Study. Mayo Clinic Proceedings. 80(10). 1291–1297. 17 indexed citations
14.
Young, Jay M., Robert Feldman, Stephen M. Auerbach, et al.. (2005). Tadalafil Improved Erectile Function at Twenty‐Four and Thirty‐Six Hours After Dosing in Men With Erectile Dysfunction: US Trial. Journal of Andrology. 26(3). 310–318. 53 indexed citations
15.
Lewis, Ronald W., Wayne J.G. Hellstrom, Marc Gittelman, et al.. (2004). 1196: Rigiscan Evaluation of TA-1790, A Novel PDES Inhibitor for the Treatment of Men with Erectile Dysfunction. The Journal of Urology. 171(4S). 316–316. 7 indexed citations
16.
Porst, Hartmut, et al.. (2003). Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology. 62(3). 519–523. 53 indexed citations
17.
Goldstein, Irwin, et al.. (2003). Vardenafil, a New Phosphodiesterase Type 5 Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes. Diabetes Care. 26(3). 777–783. 249 indexed citations
18.
Young, Jay M., et al.. (2002). Efficacy and safety of sildenafil citrate (Viagra®) in black and Hispanic American men. Urology. 60(2). 39–48. 33 indexed citations
19.
Young, Jay M.. (2002). Vardenafil. Expert Opinion on Investigational Drugs. 11(10). 1487–1496. 23 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ki Hak Moon Breakdown of academic impact, for papers by K. Rokkas Breakdown of academic impact, for papers by Roberto Bruzziches Breakdown of academic impact, for papers by C. Souto Breakdown of academic impact, for papers by Ahmet Gökçe Breakdown of academic impact, for papers by Yuanshan Cui Breakdown of academic impact, for papers by Karl Erik Andersson Breakdown of academic impact, for papers by Emre Can Polat Breakdown of academic impact, for papers by Giovanni Corona Breakdown of academic impact, for papers by Tomoya Kataoka
Rankless by CCL
2026